ROIVANT SCIENCES LTD. Restricted Cash, Current
ROIVANT SCIENCES LTD. (ROIV) had Restricted Cash, Current of $4.20 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-08-06
- 2026-06-30: Restricted Cash, Current $4.20M.
- 2026-03-31: Restricted Cash, Current $3.86M.
- 2025-12-31: Restricted Cash, Current $2.61M.
- 2025-09-30: Restricted Cash, Current $2.26M.
| Period end | Restricted Cash, Current | Restricted Cash, Current as first filed |
|---|---|---|
| 2026-06-30 | $4.20M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $3.86M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $2.61M 10-Q · filed 2026-02-06 | |
| 2025-09-30 | $2.26M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $2.26M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $2.36M 10-K · filed 2026-05-20 | |
| 2024-12-31 | $3.10M 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $3.11M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $5.41M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $3.07M 10-K · filed 2025-05-29 | $5.37M 10-K · filed 2024-05-30 |
| 2023-12-31 | $5.17M 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $5.47M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $5.26M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $5.01M 10-K · filed 2024-05-30 | |
| 2022-12-31 | $3.97M 10-Q · filed 2023-02-13 | |
| 2022-09-30 | $3.99M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $3.95M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $3.90M 10-K · filed 2023-06-28 | |
| 2021-12-31 | $2.92M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $2.86M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $2.71M 10-Q · filed 2021-09-21 | |
| 2021-03-31 | $77.70M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |